TrialAnnals of neurology2019

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid.

Ting Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.